Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
Holding RANI?
Track your performance easily
RANI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.90 - $8.75
Previous Close$2.62
Volume335.04K
Average Volume (3M)1.63M
Market Cap
$147.78M
Enterprise Value$154.85M
Total Cash (Recent Filing)$30.90M
Total Debt (Recent Filing)$35.25M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Mar 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding53,406,508
10 Day Avg. Volume549,665
30 Day Avg. Volume1,631,393
Standard Deviation0.31
R-Squared0.00033
Alpha-0.00075
Financial Highlights & Ratios
Price to Book (P/B)51.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.88
Forecast
1Y Price Target
$12.50Price Target Upside386.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Rani Therapeutics Holdings News
PremiumMarket News
3 Penny Stocks to Watch Now, 10/15/24
PremiumStock Analysis & Ideas
Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Innovative TechnologyRani Therapeutics has developed the RaniPill capsule, which is a novel, proprietary, and patented platform technology intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral administration.
Investor ConfidenceRani Therapeutics announced pricing of a $10M share purchase agreement with a single institutional investor for the sale of 3.3M shares of Class A common stock, indicating investor confidence in the company's future.
Market ExpansionRani's pipeline in psoriasis, psoriatic arthritis, hypoparathyroidism, and obesity presents an opportunity to tap into a global biologics market that reached $516B in 2022 and is expected to grow to $856B by 2031.
Bears Say
Clinical TrialsNegative clinical readouts with other candidates pose significant risks for the stock.
Market PerformanceSlower than projected market uptake for key products presents a major risk for the stock.
Regulatory ApprovalsFailure to achieve approvals for key pipeline projects, notably RT-102 and RT-105, could negatively impact the stock.
---
Options Prices
Currently, No data available
---
Ownership Overview
30.62% Insiders
2.83% Mutual Funds
1.92% Other Institutional Investors
62.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.90 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Currently, no data Available
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is Mar 19, 2025 which is in 118 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Currently, no data Available
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 32,290,066 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (386.38% Upside)
$12.50 (386.38% Upside)
Insider Transactions
Sold Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 457.5%
Last 30 Days ▲ 457.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.32%
12-Months-Change
Fundamentals
Return on Equity
-227.14%
Trailing 12-Months
Asset Growth
-47.64%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
---
RANI Earnings Call
Q4 2024
0:00 / 0:00
---
RANI Stock 12 Month Forecast
Average Price Target
$12.50
▲(386.38% Upside)
Technical Analysis
Best Analysts Covering RANI
1 Year
1 Year Success Rate
3/17 ratings generated profit
1 Year Average Return
-26.15%
reiterated a buy rating last month
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 17.65% of your transactions generating a profit, with an average return of -26.15% per trade.
---